{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T15:48:38Z","timestamp":1784562518235,"version":"3.55.0"},"reference-count":43,"publisher":"Spandidos Publications","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016,3]]},"DOI":"10.3892\/ijo.2016.3335","type":"journal-article","created":{"date-parts":[[2016,1,13]],"date-time":"2016-01-13T12:34:45Z","timestamp":1452688485000},"page":"1290-1296","source":"Crossref","is-referenced-by-count":32,"title":["KAT5 (Tip60) is a potential therapeutic target in malignant pleural mesothelioma"],"prefix":"10.3892","volume":"48","author":[{"given":"SIAN","family":"CREGAN","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"LAURAN","family":"MCDONAGH","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"YUN","family":"GAO","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"MARTIN P.","family":"BARR","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"KENNETH J.","family":"O'BYRNE","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"STEPHEN P.","family":"FINN","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"SINEAD","family":"CUFFE","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"STEVEN G.","family":"GRAY","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2249","published-online":{"date-parts":[[2016,1,13]]},"reference":[{"key":"key20180107185033_b1-ijo-48-03-1290","first-page":"260","article-title":"Diffuse pleural mesothelioma and asbestos exposure in the North Western Cape Province","volume":"17","author":"Wagner","year":"1960","journal-title":"Br J Ind Med"},{"key":"key20180107185033_b2-ijo-48-03-1290","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/S0140-6736(95)90462-X","article-title":"Continuing increase in mesothelioma mortality in Britain","volume":"345","author":"Peto","year":"1995","journal-title":"Lancet"},{"key":"key20180107185033_b3-ijo-48-03-1290","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/S0140-6736(05)67025-0","article-title":"Malignant mesothelioma","volume":"366","author":"Robinson","year":"2005","journal-title":"Lancet"},{"key":"key20180107185033_b4-ijo-48-03-1290","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1002\/ajim.20209","article-title":"The global burden of disease due to occupational carcinogens","volume":"48","author":"Driscoll","year":"2005","journal-title":"Am J Ind Med"},{"key":"key20180107185033_b5-ijo-48-03-1290","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1289\/ehp.1002845","article-title":"Global magnitude of reported and unreported mesothelioma","volume":"119","author":"Park","year":"2011","journal-title":"Environ Health Perspect"},{"issue":"Suppl 5","key":"key20180107185033_b6-ijo-48-03-1290","doi-asserted-by":"crossref","first-page":"v31","DOI":"10.1093\/annonc\/mdv199","article-title":"Malignant pleural mesothelioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"26","author":"Baas","year":"2015","journal-title":"Ann Oncol"},{"key":"key20180107185033_b7-ijo-48-03-1290","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1200\/JCO.2003.11.136","article-title":"Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma","volume":"21","author":"Vogelzang","year":"2003","journal-title":"J Clin Oncol"},{"key":"key20180107185033_b8-ijo-48-03-1290","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.cell.2012.06.013","article-title":"Cancer epigenetics: From mechanism to therapy","volume":"150","author":"Dawson","year":"2012","journal-title":"Cell"},{"key":"key20180107185033_b9-ijo-48-03-1290","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/B978-0-12-800206-3.00009-4","article-title":"Epigenetic therapy in lung cancer and mesothelioma","volume-title":"Epigenetic Cancer Therapy","author":"Baird","year":"2015","edition":"1st edition"},{"key":"key20180107185033_b10-ijo-48-03-1290","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1126\/science.1063127","article-title":"Translating the histone code","volume":"293","author":"Jenuwein","year":"2001","journal-title":"Science"},{"key":"key20180107185033_b11-ijo-48-03-1290","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/j.bbagrm.2014.03.001","article-title":"Interpreting the language of histone and DNA modifications","volume":"1839","author":"Rothbart","year":"2014","journal-title":"Biochim Biophys Acta"},{"key":"key20180107185033_b12-ijo-48-03-1290","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/j.cell.2007.10.039","article-title":"New nomenclature for chromatin-modifying enzymes","volume":"131","author":"Allis","year":"2007","journal-title":"Cell"},{"key":"key20180107185033_b13-ijo-48-03-1290","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1634\/theoncologist.12-10-1247","article-title":"FDA approval summary: Vorinostat for treatment of advanced primary cutaneous T-cell lymphoma","volume":"12","author":"Mann","year":"2007","journal-title":"Oncologist"},{"key":"key20180107185033_b14-ijo-48-03-1290","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/S1470-2045(15)70056-2","article-title":"Vorinostat in patients with advanced malignant pleural mesothelioma who have progressed on previous chemotherapy (VANTAGE-014): A phase 3, double-blind, randomised, placebo-controlled trial","volume":"16","author":"Krug","year":"2015","journal-title":"Lancet Oncol"},{"key":"key20180107185033_b15-ijo-48-03-1290","doi-asserted-by":"crossref","first-page":"4901","DOI":"10.1038\/onc.2014.453","article-title":"KATs in cancer: Functions and therapies","volume":"34","author":"Farria","year":"2015","journal-title":"Oncogene"},{"key":"key20180107185033_b16-ijo-48-03-1290","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1002\/ardp.201100209","article-title":"Small molecule inhibitors of histone acetyltransferases as epigenetic tools and drug candidates","volume":"345","author":"Furdas","year":"2012","journal-title":"Arch Pharm (Weinheim)"},{"key":"key20180107185033_b17-ijo-48-03-1290","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1093\/nar\/gkh252","article-title":"The diverse superfamily of lysine acetyltransferases and their roles in leukemia and other diseases","volume":"32","author":"Yang","year":"2004","journal-title":"Nucleic Acids Res"},{"key":"key20180107185033_b18-ijo-48-03-1290","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1007\/s00018-010-0599-9","article-title":"MYST-family histone acetyltransferases: Beyond chromatin","volume":"68","author":"Sapountzi","year":"2011","journal-title":"Cell Mol Life Sci"},{"key":"key20180107185033_b19-ijo-48-03-1290","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.gde.2004.02.009","article-title":"The highly conserved and multifunctional NuA4 HAT complex","volume":"14","author":"Doyon","year":"2004","journal-title":"Curr Opin Genet Dev"},{"key":"key20180107185033_b20-ijo-48-03-1290","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1038\/nature01035","article-title":"Acetylation of histone H4 by Esa1 is required for DNA double-strand break repair","volume":"419","author":"Bird","year":"2002","journal-title":"Nature"},{"key":"key20180107185033_b21-ijo-48-03-1290","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1093\/carcin\/bgr292","article-title":"Activation of a Tip60\/E2F1\/ERCC1 network in human lung adenocarcinoma cells exposed to cisplatin","volume":"33","author":"Van Den Broeck","year":"2012","journal-title":"Carcinogenesis"},{"key":"key20180107185033_b22-ijo-48-03-1290","doi-asserted-by":"crossref","first-page":"18218","DOI":"10.1074\/jbc.M802332200","article-title":"Tip60 is regulated by circadian transcription factor clock and is involved in cisplatin resistance","volume":"283","author":"Miyamoto","year":"2008","journal-title":"J Biol Chem"},{"key":"key20180107185033_b23-ijo-48-03-1290","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.ejmech.2011.11.001","article-title":"6-alkylsalicylates are selective Tip60 inhibitors and target the acetyl-CoA binding site","volume":"47","author":"Ghizzoni","year":"2012","journal-title":"Eur J Med Chem"},{"key":"key20180107185033_b24-ijo-48-03-1290","doi-asserted-by":"crossref","first-page":"e14593","DOI":"10.1371\/journal.pone.0014593","article-title":"Epigenetics underpinning the regulation of the CXC (ELR+) chemokines in non-small cell lung cancer","volume":"6","author":"Baird","year":"2011","journal-title":"PLoS One"},{"key":"key20180107185033_b25-ijo-48-03-1290","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1002\/jcb.25095","article-title":"Differential susceptibility of human pleural and peritoneal mesothelial cells to asbestos exposure","volume":"116","author":"Dragon","year":"2015","journal-title":"J Cell Biochem"},{"key":"key20180107185033_b26-ijo-48-03-1290","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1038\/sj.bjc.6605781","article-title":"Projection of mesothelioma mortality in Britain using Bayesian methods","volume":"103","author":"Tan","year":"2010","journal-title":"Br J Cancer"},{"key":"key20180107185033_b27-ijo-48-03-1290","doi-asserted-by":"crossref","first-page":"5372","DOI":"10.1038\/srep05372","article-title":"Rational design and validation of a Tip60 histone acetyltransferase inhibitor","volume":"4","author":"Gao","year":"2014","journal-title":"Sci Rep"},{"key":"key20180107185033_b28-ijo-48-03-1290","doi-asserted-by":"crossref","first-page":"e45539","DOI":"10.1371\/journal.pone.0045539","article-title":"Characterisation of a Tip60 specific inhibitor, NU9056, in prostate cancer","volume":"7","author":"Coffey","year":"2012","journal-title":"PLoS One"},{"key":"key20180107185033_b29-ijo-48-03-1290","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1002\/cmdc.201300478","article-title":"Rational design of substrate-based multivalent inhibitors of the histone acetyltransferase Tip60","volume":"9","author":"Yang","year":"2014","journal-title":"ChemMedChem"},{"key":"key20180107185033_b30-ijo-48-03-1290","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1172\/JCI69738","article-title":"New and emerging HDAC inhibitors for cancer treatment","volume":"124","author":"West","year":"2014","journal-title":"J Clin Invest"},{"key":"key20180107185033_b31-ijo-48-03-1290","doi-asserted-by":"crossref","first-page":"505","DOI":"10.4155\/fmc.12.3","article-title":"Targeted cancer therapy: Giving histone deacetylase inhibitors all they need to succeed","volume":"4","author":"Gryder","year":"2012","journal-title":"Future Med Chem"},{"key":"key20180107185033_b32-ijo-48-03-1290","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.1200\/JCO.2012.43.7251","article-title":"Randomized phase II, double-blind, placebo-controlled study of exemestane with or without entinostat in postmenopausal women with locally recurrent or metastatic estrogen receptor-positive breast cancer progressing on treatment with a nonsteroidal aromatase inhibitor","volume":"31","author":"Yardley","year":"2013","journal-title":"J Clin Oncol"},{"key":"key20180107185033_b33-ijo-48-03-1290","doi-asserted-by":"crossref","first-page":"djv165","DOI":"10.1093\/jnci\/djv165","article-title":"FDA approves new agent for multiple myeloma","volume":"107","author":"Fenichel","year":"2015","journal-title":"J Natl Cancer Inst"},{"key":"key20180107185033_b34-ijo-48-03-1290","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1111\/resp.12351","article-title":"A commercially available preparation of Staphylococcus aureus bio-products potently inhibits tumour growth in a murine model of mesothelioma","volume":"19","author":"Lansley","year":"2014","journal-title":"Respirology"},{"key":"key20180107185033_b35-ijo-48-03-1290","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1562\/0031-8655(2003)078<0075:ESCLIM>2.0.CO;2","article-title":"Elevated serum cytokine levels in mesothelioma patients who have undergone pleurectomy or extrapleural pneumonectomy and adjuvant intraoperative photodynamic therapy","volume":"78","author":"Yom","year":"2003","journal-title":"Photochem Photobiol"},{"key":"key20180107185033_b36-ijo-48-03-1290","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1046\/j.1365-2362.2000.00632.x","article-title":"Intrapleural administration of tumour necrosis factor-alpha (TNFalpha) in patients with mesothelioma: Cytokine patterns and acute-phase protein response","volume":"30","author":"Stam","year":"2000","journal-title":"Eur J Clin Invest"},{"key":"key20180107185033_b37-ijo-48-03-1290","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1097\/JTO.0b013e31825f22ee","article-title":"A phase II study of intermittent sunitinib malate as second-line therapy in progressive malignant pleural mesothelioma","volume":"7","author":"Nowak","year":"2012","journal-title":"J Thorac Oncol"},{"key":"key20180107185033_b38-ijo-48-03-1290","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1182\/blood-2014-05-552729","article-title":"Current concepts in the diagnosis and management of cytokine release syndrome","volume":"124","author":"Lee","year":"2014","journal-title":"Blood"},{"key":"key20180107185033_b39-ijo-48-03-1290","doi-asserted-by":"crossref","first-page":"2483","DOI":"10.1093\/annonc\/mdv387","article-title":"A phase 1b clinical trial of the CD40-activating antibody CP-870,893 in combination with cisplatin and pemetrexed in malignant pleural mesothelioma","volume":"26","author":"Nowak","year":"2015","journal-title":"Ann Oncol"},{"issue":"Suppl","key":"key20180107185033_b40-ijo-48-03-1290","doi-asserted-by":"crossref","first-page":"21S","DOI":"10.1378\/chest.109.3_Supplement.21S","article-title":"Angiogenesis in mesotheliomas. Role of mesothelial cell derived IL-8","volume":"109","author":"Antony","year":"1996","journal-title":"Chest"},{"key":"key20180107185033_b41-ijo-48-03-1290","first-page":"367","article-title":"Interleukin 8: An autocrine growth factor for malignant mesothelioma","volume":"59","author":"Galffy","year":"1999","journal-title":"Cancer Res"},{"key":"key20180107185033_b42-ijo-48-03-1290","doi-asserted-by":"crossref","first-page":"132","DOI":"10.4161\/cc.11.1.18474","article-title":"Butein impairs the protumorigenic activity of malignant pleural mesothelioma cells","volume":"11","author":"Cioce","year":"2012","journal-title":"Cell Cycle"},{"key":"key20180107185033_b43-ijo-48-03-1290","first-page":"187","article-title":"Inhibition of interleukin-8 reduces human malignant pleural mesothelioma propagation in nude mouse model","volume":"11","author":"Galffy","year":"1999","journal-title":"Oncol Res"}],"container-title":["International Journal of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/spandidos-publications.com\/10.3892\/ijo.2016.3335\/download","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,13]],"date-time":"2020-09-13T22:47:10Z","timestamp":1600037230000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.spandidos-publications.com\/10.3892\/ijo.2016.3335"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,1,13]]},"references-count":43,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2016,1,13]]},"published-print":{"date-parts":[[2016,3]]}},"alternative-id":["10.3892\/ijo.2016.3335"],"URL":"https:\/\/doi.org\/10.3892\/ijo.2016.3335","relation":{},"ISSN":["1019-6439","1791-2423"],"issn-type":[{"value":"1019-6439","type":"print"},{"value":"1791-2423","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,1,13]]}}}